DX9 Stock Overview
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Deltex Medical Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.024 |
| 52 Week Low | UK£0.0005 |
| Beta | 0.82 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| DX9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.3% |
| 1Y | n/a | -10.1% | 2.8% |
Return vs Industry: Insufficient data to determine how DX9 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how DX9 performed against the German Market.
Price Volatility
| DX9 volatility | |
|---|---|
| DX9 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DX9 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DX9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Andy Mears | www.deltexmedical.com |
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers oesophageal Doppler Probes that is used to measure a patient’s central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting.
Deltex Medical Group plc Fundamentals Summary
| DX9 fundamental statistics | |
|---|---|
| Market cap | €3.32m |
| Earnings (TTM) | -€1.19m |
| Revenue (TTM) | €2.78m |
1.2x
P/S Ratio-2.8x
P/E RatioIs DX9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DX9 income statement (TTM) | |
|---|---|
| Revenue | UK£2.38m |
| Cost of Revenue | UK£668.00k |
| Gross Profit | UK£1.72m |
| Other Expenses | UK£2.74m |
| Earnings | -UK£1.02m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00054 |
| Gross Margin | 71.97% |
| Net Profit Margin | -42.80% |
| Debt/Equity Ratio | 116.6% |
How did DX9 perform over the long term?
See historical performance and comparison